Results 151 to 160 of about 32,411 (197)
Some of the next articles are maybe not open access.
Blood Reviews, 1989
The accepted role for thrombolytic therapy has until recently been limited because of its complexity and side-effects. It has generally been reserved for use systemically in a limited number of patients with acute, major pulmonary embolism or iliofemoral venous thrombosis, and locally in some patients with acute, peripheral arterial occlusion.
openaire +2 more sources
The accepted role for thrombolytic therapy has until recently been limited because of its complexity and side-effects. It has generally been reserved for use systemically in a limited number of patients with acute, major pulmonary embolism or iliofemoral venous thrombosis, and locally in some patients with acute, peripheral arterial occlusion.
openaire +2 more sources
Monitoring thrombolytic therapy
Progress in Cardiovascular Diseases, 1992HROMBOLYTIC THERAPY for acute myocardial infarction (MI) now represents the standard of care for many patients. A large number of clinical trials have demonstrated improvement in survival and cardiac function following treatment of acute MI with thrombolytic agents,‘.’ and the use of thrombolytic therapy is rapidly spreading to community hospitals.
E G, Bovill, R, Becker, R P, Tracy
openaire +2 more sources
Advances in Thrombolytic Therapy
Drug Intelligence & Clinical Pharmacy, 1982Streptokinase and urokinase are the two thrombolytic agents currently available in the United States. These drugs promote dissolution of thrombi by stimulating the conversion of plasminogen to plasmin, resulting in an overall “lytic state” in the blood. Recent clinical trials in patients with pulmonary emboli, deep vein thrombosis, arterial thrombosis,
D M, Rutkowski, W S, Burkle
openaire +2 more sources
Thrombolytic therapy for stroke
Current Opinion in Neurology, 1994The physiology of thrombi and the pharmacology of thrombolytic drugs are under active study and improved regimens for the dosing of thrombolytic agents have been developed. In the setting of myocardial infarction, recently reported differences among thrombolytic agents have been slight, including the frequency of thrombolysis-associated hemorrhagic ...
T, Brott, J, Broderick, R, Kothari
openaire +2 more sources
Applications of thrombolytic therapy
Intensive Care Medicine, 1998Formation of a thrombus involves the aggregation of platelets, precipitation of fibrinogen into a fibrin meshwork and subsequent trapping of red blood cells. The coagulation cascades ensure that this process is initiated in response to a wide range of stimuli including local vessel trauma, endothelial damage and systemic inflammation.
N, Curzen, R, Haque, A, Timmis
openaire +2 more sources
Thrombolytic therapy in the elderly
The Lancet, 2000Elderly patients have the highest absolute risk of death following an acute myocardial infarction (MI); 16.1% for those aged between 65 and 74 years, and 25.3% for those older than 75 years. Therefore, this age-group potentially may benefit most from the use of thrombolytic therapy.
openaire +2 more sources
Thrombolytic therapy in pregnancy
Journal of Thrombosis and Thrombolysis, 2006Pregnancy due to its physiological changes is a procoagulant state. The rate of cardiac valve prosthesis thrombosis, deep venous thrombosis and pulmonary embolism are all increased. Thrombolytic therapy with tissue plasminogen activator (rt-PA) is an approved therapy for ischemic stroke, myocardial infarction, pulmonary embolism and thrombosis of ...
Georg, Leonhardt +4 more
openaire +2 more sources
The American Journal of Cardiology, 1991
In the past decade, mortality associated with acute myocardial infarction has been reduced to between 5% and 9% in selected groups of patients, largely due to use of early reperfusion. Thrombolytics combined with aggressive mechanical revascularization reduce the likelihood of death both during hospitalization and in the ensuing several years.
openaire +2 more sources
In the past decade, mortality associated with acute myocardial infarction has been reduced to between 5% and 9% in selected groups of patients, largely due to use of early reperfusion. Thrombolytics combined with aggressive mechanical revascularization reduce the likelihood of death both during hospitalization and in the ensuing several years.
openaire +2 more sources
Blood Reviews, 2001
T hrombolytic therapy represents part of a conjoint approach to achieving vascular reperfusion, based primarily on the use of fibrinolytic agents delivered systemically or directly into the offending thrombus and complemented by anticoagulation, antiplatelet, and even mechanical strategies.
openaire +2 more sources
T hrombolytic therapy represents part of a conjoint approach to achieving vascular reperfusion, based primarily on the use of fibrinolytic agents delivered systemically or directly into the offending thrombus and complemented by anticoagulation, antiplatelet, and even mechanical strategies.
openaire +2 more sources
Advances in thrombolytic therapy
Cardiovascular Drugs and Therapy, 1992Alteplase and saruplase are more fibrin-specific thrombolytic drugs than anistreplase. These and the thrombolytic drugs of the first generation (streptokinase and urokinase) have shortcomings and limitations. The prolonged intravenous maintenance infusions have been replaced by a bolus injection, accelerated infusions, or the combined intravenous ...
openaire +2 more sources